New Analytical Method Quantifies TB-500 and Metabolites for Wound Healing

The synthetic peptide TB-500, a fragment of naturally occurring Thymosin Beta-4, is widely recognized for its potent wound healing, tissue regeneration, and anti-inflammatory properties. Despite its therapeutic potential, a comprehensive understanding of its metabolic fate and the biological activity of its metabolites has been lacking, which is crucial for optimizing its clinical application. This study addresses this knowledge gap by developing a robust analytical method to simultaneously quantify TB-500 and its metabolites in biological samples and assess their in-vitro wound healing capabilities.

The developed UHPLC-Q-Exactive orbitrap MS/MS method successfully identified and quantified 4 major metabolites of TB-500 in both in-vitro and in-vivo samples, demonstrating high sensitivity with a lower limit of quantification (LLOQ) of 0.5 ng/mL. In the rat model, TB-500 reached its peak plasma concentration (Cmax) of 125 ng/mL at approximately 1 hour post-injection, with an estimated half-life of 3.5 hours. One primary metabolite, identified as Ac-LKKTETQ-OH (a truncated form), was detected at significant levels, peaking at 2 hours and showing a slower elimination rate than the parent compound. > The most active metabolite, Metabolite X (Ac-LKKTETQ-OH), demonstrated 70% of the wound healing efficacy of the parent TB-500 in fibroblast migration assays, indicating its substantial contribution to the peptide's overall therapeutic effects. Another metabolite, Metabolite Y, showed 45% activity, while the remaining 2 metabolites exhibited negligible in-vitro wound healing potential, suggesting specific metabolic pathways yield active compounds.